KemPharm, Inc. (KMPH) Q3 2022 Earnings Call Transcript

SA Transcripts
154.12K Followers

Q3: 2022-11-09 Earnings Summary

EPS of -$0.19 misses by $0.03
 | Revenue of $2.87M (46.26% Y/Y) misses by $138.33K

KemPharm, Inc. (KMPH) Q3 2022 Results Conference Call November 9, 2022 5:00 PM ET

Company Participants

Nichol Ochsner - Vice President of Investor Relations
Travis Mickle - President and Chief Executive Officer
LaDuane Clifton - Chief Financial Officer

Conference Call Participants

Sumant Kulkarni - Canaccord
Jonathan Aschoff - Roth Capital Partners

Operator

Good afternoon, and welcome to the KemPharm Third Quarter 2022 Corporate and Financial Results Conference Call. Currently, all callers have been placed in a listen-only mode and following management’s prepared remarks, the call will be opened up for questions. [Operator Instructions] Please be advised that today’s call is being recorded.

I will now turn the call over to Nichol Ochsner, KemPharm’s Vice President, Investor Relations and Corporate Communications. Thank you. Ma’am, you may begin.

Nichol Ochsner

Good afternoon and thank you for joining our call to discuss KemPharm’s third quarter 2022 financial and corporate results.

Before we begin, I would like to remind our listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties and are subject to changes at any time, including but not limited to, statements about KemPharm’s expectations regarding future operating results. Forward-looking statements are made pursuant to the Safe Harbor provisions of the federal securities laws and represent management’s current expectations. Actual results may differ materially.

KemPharm disclaims any obligation to update or revise forward-looking statements except as required by law. For complete information regarding forward-looking statements, risks and uncertainties can be found in KemPharm’s filings with the SEC, which are available on KemPharm’s website under the Investor Relations section.

Speaking on today’s call will be Travis Mickle, KemPharm’s President and CEO; and LaDuane Clifton, CFO. Following remarks Travis and LaDuane will participate in a question-and-answer session.

With that it is my pleasure to introduce, Travis.

Travis Mickle

Recommended For You

About ZVRA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ZVRA